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Abstract The integrin family of cell adhesion receptors is
emerging as a promising target of anticancer therapy.
AlphaVbeta3 and alphaVbeta5 integrins are overexpressed
on both glioma cells and tumor vasculature. Cilengitide, the
most advanced specific integrin inhibitor in oncology, has
shown antitumor activity against glioma in early clinical
trials. Durable remissions have been observed in phase I
and phase II trials for recurrent glioblastoma (GBM) with
both lower and higher doses of cilengitide. Pilot trials in
newly diagnosed glioblastoma in conjunction with standard
chemoradiotherapy have been encouraging. Preclinical data
suggest synergy with concomitant chemo- and radiation
therapy. A pivotal phase III study (CENTRIC) in newly
diagnosed GBM patients is currently recruiting. This paper
summarizes the current understanding of the role of
integrins and their inhibition in gliomagenesis. The back-
ground and design of ongoing trials are outlined.
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Introduction
Integrins are heterodimeric transmembrane cell surface
receptors that play a key role in the crosstalk between the
cell and its surrounding stroma [1]. Twenty-four different
integrins have been identified to date. Integrins link the
G. Tabatabai (*) :M. Weller
Department of Neurology, University Hospital Zurich,
Frauenklinikstrasse 26,
8091 Zurich, Switzerland
e-mail: ghazaleh.tabatabai@usz.ch
M. Weller
e-mail: michael.weller@usz.ch
B. Nabors
Department of Neurology, University of Alabama at Birmingham,
Birmingham, AL, USA
M. Picard
Global Clinical Development Unit Oncology, Merck KGaA,
Frankfurter Strasse 250,
64293 Darmstadt, Germany
D. Reardon
Departments of Surgery and Pediatrics, The Preston Robert Tisch
Brain Tumor Center, Duke University Medical Center,
Durham, NC, USA
T. Mikkelsen
Department of Neurosurgery, Hermelin Brain Tumor Center,
Henry Ford Hospital,
Detroit, MI, USA
T. Mikkelsen
Department of Neurology, Hermelin Brain Tumor Center,
Henry Ford Hospital,
Detroit, MI, USA
C. Ruegg
Division of Experimental Oncology, Centre Pluridisciplinaire
d’Oncologie, Faculty of Biology and Medicine,
University of Lausanne, and NCCR Molecular Oncology
ISREC-EPFL,
Epalinges, Switzerland
C. Ruegg
Pathology, Med3, Department of Medicine, Faculty of Science,
University of Fribourg,
Fribourg, Switzerland
R. Stupp (*)
Department of Neurosurgery, Centre Hospitalier Universitaire
Vaudois (CHUV) and University of Lausanne,
Lausanne, Switzerland
e-mail: roger.stupp@chuv.ch
Targ Oncol (2010) 5:175–181
DOI 10.1007/s11523-010-0156-3
cytoskeleton to the extracellular matrix, and are recognized
to be key regulators of tissue structure. Integrins regulate
cell adhesion, migration, differentiation, proliferation, and
survival during physiological and pathological conditions,
including inflammation and cancer. Upon ligation to
extracellular ligands (i.e., matrix proteins such as collagens,
laminins, vitronectins and fibronectins), integrins activate
downstream signaling pathways in concert with growth
factor receptors, including platelet-derived growth factor
receptor (PDGFR), epidermal growth factor receptor
(EGFR) and vascular endothelial growth factor receptor
(VEGFR).
Preclinical data indicate that integrins play a key role in
cancer initiation and progression [2]. They provide adhe-
sive, migratory, and survival cues to tumor cells and to cells
of the tumor microenvironment, including angiogenic
endothelial cells. The integrins alphaVbeta3 and alphaV-
beta5, among others, are highly expressed not only on the
tumor vasculature and angiogenic endothelial cells, but also
on tumor cells, including gliomas (reviewed in [3, 4]).
Consequently, integrins have been considered as a promis-
ing therapeutic target in cancer [5]. Monoclonal antibodies
and peptide-based integrin inhibitors are being investigated
for their potential therapeutic activity in various tumor
types. This strategy is in advanced stage clinical develop-
ment in glioblastoma, a highly vascular primary brain
tumor. The only integrin inhibitor being studied in glioma is
cilengitide, we therefore focus this short review on this
agent.
Preclinical data on integrins in glioma
In high-grade glioma, and in particular in glioblastoma,
overexpression of alphaVbeta3 integrin is well docu-
mented. Importantly, alphaVbeta3 integrin is expressed
both on angiogenic endothelial cells and on tumor cells
[6–8]. Molecular imaging of alphaVbeta3 expression using
the tracer [18F]Galacto-RGD and validation by immuno-
histochemistry revealed that alphaVbeta3 integrin expres-
sion was mainly confined to the tumor region and was
absent in normal tissue [9]. Selective alphaVbeta3 upregu-
lation in malignant gliomas suggests that integrin signaling
in glioblastoma has important functions. Emerging evi-
dence indicates that integrins promote glioblastoma adhe-
sion, migration and angiogenesis [10, 11]. In an autocrine
loop hypoxia will recruit alphaVbeta3 and alphaVbeta5
integrins and activate focal adhesion kinase (FAK). Integrin
inhibition decreases hypoxia-inducible factor 1alpha (HIF-
1alpha) and reduces thus tumor hypoxia, which may lead to
increased radiation sensitivity [12].
The integrin alpha6beta1 plays an important role for the
regulation of glioma-initiating cells in the perivascular
niche [13]. This integrin mediates the interaction of
glioma-initiating cells to laminin, an extracellular matrix
protein expressed in basement membranes, including those
supporting endothelial cells. This interaction provides an
anchorage for glioma-initiating cells within the perivascular
niche and supports their tumorigenic potential.
Given the role of integrins in promoting glioma growth,
invasion and angiogenesis, integrin inhibitors might be
ideal therapeutic tools with synergistic activities in con-
junction with already established therapeutic modalities,
i.e., radiation therapy and cytotoxic chemotherapy. Impor-
tantly, because of their antiangiogenic effects [14], integrin
inhibitors are expected to normalize the tumor vasculature,
which in turn might enhance the effects of radiation therapy
and chemotherapy. Indeed the efficacy of these two
therapeutic modalities depends on an effective blood
perfusion for oxygenation of the tumor (i.e., an important
condition for radiation-induced tumor cell killing) and
optimal drug delivery. Inhibition of alphaVbeta3 and
alphaVbeta5 integrins in hypoxic glioma cells by siRNA
decreases HIF-1alpha by regulating FAK. Silencing this
signaling cascade in established xenografts indeed reduced
hypoxia and decreased angiogenesis [12].
Interestingly, ionizing radiation induces ceramide-
mediated apoptosis of tumor endothelial cells, causing tumor
vessel disruption and delayed tumor growth [15]. Consistent
with a cytotoxic effect of radiotherapy on angiogenic vessels,
concomitant administration of antiangiogenic drugs
decreases endothelial cell survival. Anti-VEGF antibodies
(e.g., bevacizumab) [16], VEGFR inhibitors (e.g., AG-
013736) [17], mTOR inhibitors (e.g., RAD001) [18], and
integrin inhibition (cilengitide) [19] sensitize angiogenic
endothelial cells to ionizing radiation-induced death, thereby
enhancing tumor vascular damage induced by radiotherapy
and improving therapeutic response [20]. Irradiation of
glioma cells increases their expression of alphaVbeta3
integrin [21], thus integrin inhibition will further synergize
with radiation therapy.
Regarding clinical translation, targeting alphavbeta3 and
alphavbeta5 might reduce hypoxia and thus resistance to
radio- and/or chemotherapy [12]. Indeed, arresting integrin
signaling synergistically enhances the anti-glioma effect of
radiation therapy in vivo [22].
A recent preclinical study suggests that low concen-
trations of small molecular integrin inhibitors used as single
agents may stimulate angiogenesis and tumor growth in
experimental melanoma and Lewis Lung carcinoma mod-
els, through increased VEGF expression and VEGFR2
signaling [23]. The concentrations of the small molecular
integrin inhibitor cilengitide, measured in patients in
clinical trials, however, largely exceed the critical “proan-
giogenic” concentrations described in this preclinical study,
and therefore, paradoxical proangiogenic effects of small
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molecular integrin inhibitors in the clinical application
seem rather unlikely [24]. In fact, relative cerebral blood
volume and blood flow, measured by perfusion MRI,
remained stable or decreased among recurrent GBM
patients responding to cilengitide therapy in a prior phase
I study [25]. Durable and clinically relevant responses have
been observed with cilengitide monotherapy; ongoing
clinical studies administer cilengitide in combination with
radiotherapy and/or chemotherapy. Nevertheless, the dura-
ble therapeutic success will depend on the efficient
management of escape mechanisms occurring under anti-
integrin therapies [26, 27].
Integrin inhibition attenuates invasion and metastasis
secondary to radiation-induced angiogenesis inhibition
Vascular normalization may not be the only mechanism by
which integrin inhibitors synergize with radio-
chemotherapy. We have recently observed that high doses
of ionizing radiation locally suppress angiogenesis in vivo
and inhibited endothelial cell sprouting in vitro through a
cell-autonomous effect mediated by the TGFbeta receptor
ALK5 [28]. Tumors derived from oral squamous cell
carcinoma and from hepatoma cell lines growing within a
pre-irradiated bed had decreased microvascular density and
were smaller, but their margins were highly invasive. They
also had increased hypoxia and necrosis, and a more
aggressive behavior with a higher number of lung metas-
tases [29]. Thus, pre-irradiation of the tumor bed reduces
local tumor growth, likely due to acute metabolic starvation
secondary to suppressed angiogenesis, but at the same time
it may enhance local invasion and metastatic spreading,
possibly through increased hypoxia. We have identified the
cysteine-rich protein 61 (CYR61), a member of the CCN
(CYR61/CTGF/NOV) family of matricelluar proteins reg-
ulating cell growth, differentiation, survival and migration
in development, tissue remodeling and repair [30], and
integrin alphaVbeta5 (a receptor for CYR61) expressed by
tumor cells, as critical molecules that cooperate to promote
local invasion and distant metastases [29]. Importantly,
function-blocking anti-αV mAb 17E6 [29, 31] and
cilengitide-inhibited CYR61-mediated invasion and metas-
tasis formation of tumor cells growing in a pre-irradiated
bed. These results suggest that cilengitide may improve
cancer control in conjunction with radiotherapy by
attenuating some of the unwanted rebound effect of
radiation-induced inhibition of angiogenesis. Hypoxia is
well known to activate pro-invasive programs [32] and
select for resistant variants with invasive characteristics.
This view is consistent with a recent experimental study
demonstrating that selected inhibition of tumor angiogen-
esis by antiangiogenic drugs, including in experimental
glioma, results in increased invasion and metastasis
formation [33].
Cilengitide
Cilengitide (Merck KGaA, Darmstadt, Germany) is a
synthetic Arg-Gly-Asp (RGD) pentapeptide recognizing
the RGD ligand-binding motif (ligand binding site) on the
integrin receptors alphaVbeta3 and alphaVbeta5 [34, 35]
and competitively blocks integrin ligand binding. It was
shown to diminish angiogenesis in vitro [36]. In an
important early preclinical study, cilengitide markedly
suppressed tumor growth in a medulloblastoma and
orthotopic glioblastoma models (i.e., tumors were grown
in the brain), while no growth inhibition was demonstrated
in a heterotopic model (i.e., when tumors were grown in
the flank of nude mice), or when an inactive peptide was
used [37]. This suggests that the brain environment is
particularly susceptible to integrin inhibition and led to
subsequent clinical investigation.
In phase I studies cilengitide was administered twice
weekly by intravenous infusion over 1 h. No dose limiting
toxicity was observed with doses up to 2400 mg/m2. Peak
plasma concentrations that had shown antitumor effects in
preclinical models were achieved at doses ≥120 mg/m2 [25,
38–40]. The terminal half-life of cilengitide is 3–5 h,
suggesting the possibility of increased efficacy with a more
frequent administration or continuous infusion schedule.
Clinical experience with cilengitide in malignant glioma
Sustained responses in recurrent glioblastoma were seen
both with lower and higher doses of cilengitide as single
agent in two phase I trials in adult and pediatric patients
[25, 39]. Overall cilengitide was well tolerated, a maximal
tolerated dose not reached and a clinical benefit seen both
at higher and lower doses. Subsequent trials were initiated
with flat (not per m2) twice weekly dosing of cilengitide at
an intermediate lower (500 mg) and intermediate higher
(2000 mg) dose (Table 1). In a randomized phase II trial of
81 patients with recurrent glioblastoma, treatment was
administered at the lower and higher dose. Cilengitide
monotherapy was well tolerated independently of the dose.
Objective responses were achieved in 5% or 13% of
patients treated with 500 mg or 2000 mg, respectively.
Progression-free survival after 6 months was 10% and 15%,
whereas overall survival was in the range of 6.5 versus
9.9 months, respectively [41]. Recently, long-term survival
results were reported demonstrating a 4-year survival rate
of 2.4% (95%CI 0.2; 11%) in patients treated with the
lower dose, and 10.0% (95%CI 3.2; 21.5%) in patients
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treated with the higher dose of cilengitide [42]. Similarly, a
phase II randomized trial evaluating lower (500 mg) and
higher (2000 mg) doses cilengitide added to temozolomide
and radiotherapy (TMZ/RT) in newly diagnosed glioblas-
toma patients was reported in abstract form [43]. Median
survival was 18.9 months, with an estimated median
survival of 17 months and 21 months, for the lower and
higher dose, respectively. Finally, higher exposure of the
tumor tissue could be demonstrated in another randomized
trial evaluating 3 doses of either 500 mg or 2000 mg
cilengitide prior to tumor resection in recurrent disease.
Cilengitide concentrations were several-fold higher in the
tumor than the corresponding plasma concentrations,
demonstrating both excellent penetration through the
blood-tumor barrier and retention within the tumor. Impor-
tantly, safety could be confirmed and no increase in
bleeding complications or wound healing problems were
observed [44].
Consistently, the higher dose of cilengitide is favored
by exposure, responses, progression-free and overall
survival.
Based on a strong preclinical rationale of radiosensitiza-
tion and synergy with both cilengitide and irradiation and
TMZ, we designed in parallel to the above-mentioned trials
a phase II pilot trial of adding cilengitide (500 mg) to
standard chemoradiotherapy with TMZ (TMZ/RT→TMZ)
[45, 46].
In a multicenter pilot study on 52 patients, treatment
was well tolerated with no identifiable added toxicity.
The primary endpoint of progression-free survival at
6 months compared favorably with historical controls
(69% versus 54%) [46, 47]. Median survival was
16.1 months, with a 2-year survival rate of 35% [45].
Interestingly, the outcome was particularly good in
patients with a methylated O6-methylguanine–DNA meth-
yltransferase (MGMT) gene promoter, Such patients were
previously identified to particularly benefit from TMZ
chemotherapy [48]. This is consistent with the working
hypothesis, that antiangiogenic therapy may lead to
normalization of tumor vasculature, decrease of hypoxia,
improved drug delivery and enhanced cytotoxicity. In
addition, the currently used higher dose of 2000 mg
should also exert relevant direct antitumor activity and
directly synergize with standard chemoradiotherapy.
Building on our pilot experience and the consistent
encouraging results of the other clinical trials in malignant
glioma, Merck KGaA in collaboration with the European
Organisation for Research and Treatment of Cancer
(EORTC) and the Canadian Brain Tumor Consortium is
sponsoring a large prospective clinical phase III trial
(CENTRIC study, Fig. 1) [49]. Based on the suggested
synergy between normalized perfusion and active chemo-
therapy, only patients with a methylated MGMT are eligible.
This requires centralized upfront MGMT testing, and it is
the first prospective international clinical oncology trial
incorporating this novel molecular marker to homogenously
define the treated patient population. Other changes from
the previous phase II trial are the exclusive use of the
higher dose of cilengitide (2000 mg), and cilengitide
maintenance therapy for up to 18 months. In parallel a
separate 3-arm randomized phase II trial has been designed
for patients with MGMT unmethylated tumors (CORE
study). Here an intensified high-dose daily cilengitide
administration before radiotherapy is being explored. Early
data indicate that this schedule is well tolerated and safe,
and the trial is now ongoing in a multicenter setting. The
results of all completed brain tumor clinical trials using
cilengitide are summarized in Table 1.
Conclusions
The ongoing phase III CENTRIC trial is successfully
recruiting in a multi-national setting and is expected to be
completed by the end of the year 2010. Careful analysis of
data emerging from this trial will make an important
contribution to further defining the role on integrin inhibition
in malignant gliomas. The absence of significant toxicity and
excellent tolerance will allow to safely testing integrin-
inhibition in combination with other targeted and cytotoxic
agents. Combined inhibition of integrins and VEGF may lead
to further enhancement and increased antitumor effect, and
clinical evaluation of this concept is warranted.
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